Literature DB >> 23697474

Primary nonadherence to statin medications in a managed care organization.

T Craig Cheetham1, Fang Niu, Kelley Green, Ronald D Scott, Stephen F Derose, Southida S Vansomphone, Janet Shin, Kaan Tunceli, Kristi Reynolds.   

Abstract

BACKGROUND: Primary nonadherence to a medication occurs when a drug is prescribed but the patient fails to pick the prescription up from the pharmacy. Managed care organizations that provide integrated care using electronic medical records (EMR) are an ideal setting to study primary nonadherence.
OBJECTIVE: To identify patient and provider characteristics that are significantly associated with primary nonadherence to statin medications compared with a population of patients who picked up their first statin order.
METHODS: This was a retrospective cohort study of patients with a new statin prescription. Patients with a new order for a statin prescription between December 1, 2009, and February 28, 2010, were eligible. A statin order was considered new if the patient had no statin prescriptions in the previous 12 months. Study participants were 24 years and older with 12 months of continuous membership prior to the statin order. Patients were defined as primary nonadherent if they did not pick up their new prescription within 90 days. Descriptive and multivariate (conditional logistic regression) analyses of patients who did and did not pick up their new statin prescriptions were performed using demographic and socioeconomic information, health care utilization, health conditions, medical benefits, and prescriber characteristics.
RESULTS: A total of 19,826 patients with a new statin order that met all of the inclusion and exclusion criteria was identified. Of these, 3,049 patients (15.4%) did not pick up their statin prescriptions within 90 days of the order date. Primary nonadherent patients tended to be younger (55 vs. 57 years, P  less than  0.001) and healthier, with fewer comorbid conditions (Charlson Comorbidity Index ≥ 1, 42.2% vs. 52.3%, P  less than  0.001), lower rates of hospitalizations (7.2% vs. 12.0%, P  less than  0.001), fewer concurrent prescriptions (3 vs. 4, P  less than  0.001) and fewer clinic (4 vs. 5, P  less than  0.001) and emergency department visits (18.2% vs. 24.6%, P  less than  0.001) in the prior year than adherent patients. Although the multivariate model agreed well with the observed data, the characteristics included had a poor ability to predict primary nonadherence (c-statistic = 0.603).
CONCLUSION: Primary nonadherence has been recognized as a significant problem for many years, and electronic health records are allowing researchers to investigate the extent of the problem. In this study, almost 1 in 6 patients (15.4%) failed to pick up their new statin order within 90 days. However, clinical and demographic information available in electronic health care data may not be useful in predicting primary nonadherence. New methods and interventions need to be developed to improve primary adherence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23697474     DOI: 10.18553/jmcp.2013.19.5.367

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  18 in total

1.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

Review 2.  Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?

Authors:  Stefan Weisshaar; Markus Zeitlinger
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

3.  How do we better translate adherence research into improvements in patient care?

Authors:  Adam La Caze; Gina Gujral; William Neil Cottrell
Journal:  Int J Clin Pharm       Date:  2014-02

4.  Refractory primary medication nonadherence: Prevalence and predictors after pharmacist counseling at hospital discharge.

Authors:  Kathleene Wooldridge; Jeffrey L Schnipper; Kathryn Goggins; Robert S Dittus; Sunil Kripalani
Journal:  J Hosp Med       Date:  2015-08-21       Impact factor: 2.960

5.  Time to Filling of New Prescriptions for Chronic Disease Medications Among a Cohort of Elderly Patients in the USA.

Authors:  Jessica M Franklin; Mufaddal Mahesri; Alexis A Krumme; Julie Barberio; Michael A Fischer; Gregory Brill; Caroline McKay; Heather Black; Niteesh K Choudhry
Journal:  J Gen Intern Med       Date:  2018-07-27       Impact factor: 5.128

Review 6.  When compliance is an issue-how to enhance statin adherence and address adverse effects.

Authors:  Kim Birtcher
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

7.  Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network.

Authors:  Brent M Egan; Susan E Sutherland; William F Childers; Ruthanne M Dahlheimer; George A Helmrich; Daryl A Lapeyrolerie; Nancy Markle; Dennis W Murphy; Locke Simmons; Robert A Davis; Peter Tilkemeier; Angelo Sinopoli
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-04

8.  Perceptions of Patients with Primary Nonadherence to Statin Medications.

Authors:  Derjung M Tarn; Maureen Barrientos; Mark J Pletcher; Keith Cox; Jon Turner; Alicia Fernandez; Janice B Schwartz
Journal:  J Am Board Fam Med       Date:  2021 Jan-Feb       Impact factor: 2.657

9.  Adherence to statin therapy in patients with type 2 diabetes: An important dilemma.

Authors:  Shadi Farsaei; Ali Mohammad Sabzghabaee; Masoud Amini; Amir Hooshang Zargarzadeh
Journal:  J Res Med Sci       Date:  2015-02       Impact factor: 1.852

10.  Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry.

Authors:  Brent M Egan; Jiexiang Li; Douglas O Fleming; Kellee White; Kenneth Connell; Robert A Davis; Angelo Sinopoli
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-11-26       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.